发明名称 |
Cancer patient selection for administration of therapeutic agents using mass spectral analysis |
摘要 |
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a solid epithelial tumor cancer patient is likely to benefit from a therapeutic agent or a combination of therapeutic agents targeting agonists of the receptors, receptors or proteins involved in MAPK (mitogen-activated protein kinase) pathways or the PKC (protein kinase C) pathway upstream from or at Akt or ERK/JNK/p38 or PKC, such as therapeutic agents targeting EGFR and/or HER2. The methods also provide the ability to determine whether the cancer patient is likely to benefit from the combination of a therapeutic agent targeting EFGR and a therapeutic agent targeting COX2; or whether the cancer patient is likely to benefit from the treatment with an NF-κB inhibitor. |
申请公布号 |
AU2011219069(C1) |
申请公布日期 |
2014.07.17 |
申请号 |
AU20110219069 |
申请日期 |
2011.02.22 |
申请人 |
BIODESIX, INC. |
发明人 |
GRIGORIEVA, JULIA;RODER, HEINRICH;TSYPIN, MAXIM |
分类号 |
G01N30/72;G01N33/48 |
主分类号 |
G01N30/72 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|